Reports on Enzyme Inhibition and Medicinal Chemistry Findings from Menoufia University Provide New Insights (Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2-a] pyrimidines as topoisomerase II inhibitors).

A study conducted at Menoufia University in Egypt has explored the design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2-a] pyrimidines as topoisomerase II inhibitors. The researchers synthesized several compounds and evaluated their cytotoxicity against human tumor cell lines. They found that certain compounds exhibited potent anticancer activity, comparable or superior to Doxorubicin. The most potent topoisomerase II inhibitor was compound 4c, which showed significant cell cycle disruption and apoptosis on A549 cells. Molecular docking analysis suggested that the designed compounds have potential as effective anticancer agents through topoisomerase II inhibition. [Extracted from the article]